Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06866405 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
A Phase 3 study of RSV Infection, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 550
- Enrollment target
- 20
- Study locations
NCT06866405: Recruiting Phase 3 study of RSV Infection, sponsored by Pfizer.
NCT06866405 is a Phase 3 study of RSV Infection that is actively recruiting participants, run by Pfizer. The registered enrollment target is 550 participants, below the 678-participant average among 8 other RSV Infection trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06866405, a Phase 3 study of RSV Infection, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 550 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous pregnancy by examining the blood of nonpregnant participants who had the vaccine before.
Primary Outcome
Pain at the injection site, redness, and swelling
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL RSVpreF
Study Locations (20)
California
- Ronald Reagan UCLA Medical Center - Los Angeles
- Ronald Reagan UCLA Medical Center (inpatient hospital) - Los Angeles
- Ronald Reagan UCLA Medical Center - Los Angeles
- UCLA (outpatient clinic) - Los Angeles
- UCLA Clinical and Translational Research Center (research clinic) - Los Angeles
- UCLA - Los Angeles
- Lucile Packard Children's Hospital-Labor and Delivery Unit - Palo Alto
- Stanford Obstetrics Clinic - Palo Alto
- Stanford University Medical Center - Palo Alto
- Stanford University - Palo Alto
Alabama
- Center for Research in Women's Health - Birmingham
- Children's of Alabama - Birmingham
- University of Alabama at Birmingham - School of Medicine - Birmingham
- University of Alabama at Birmingham Women & Infants Center - Birmingham
- USA Health Children's and Women's Hospital - Mobile
- USA Health Strada Patient Care Center - Mobile
Colorado
- Anschutz Health Sciences Building (AHSB) - Aurora
- Children's Hospital Colorado - Aurora
- CU Research Pharmacy - Aurora
- University of Colorado AO1 UCH - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2025-04-16 |
| Est. Completion | 2028-02-24 |
| Phase | Phase 3 |
What NCT06866405 shows while recruiting
NCT06866405 is an interventional study that assigns participants to a tested intervention. The registered 550 participants enrollment target is mid-sized for trials with a published cap, below the 678-participant average among 8 other RSV Infection trials with a reported enrollment target (19% lower).
The record links to 1 condition, with RSV Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06866405 names 20 study sites across 3 states, led by California, Alabama, Colorado.
Frequently Asked Questions
What is clinical trial NCT06866405 about?
NCT06866405 is a clinical study titled "A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose". This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous pregnancy by examining the blood of nonpregnant participants who had the vaccine before.
What is the current status of trial NCT06866405?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 550 participants. The study started on 2025-04-16. Estimated completion is 2028-02-24.
What conditions does trial NCT06866405 study?
This clinical trial studies the following conditions: RSV Infection.
What interventions are being tested in trial NCT06866405?
The interventions under investigation include: Placebo (BIOLOGICAL), RSVpreF (BIOLOGICAL).
Who is sponsoring clinical trial NCT06866405?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06866405 being conducted?
This trial has 20 study locations across Alabama, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for RSV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06866405's enrollment target sits among peer trials
550 3rd of 8 higher than 6 of 8 other RSV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other RSV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
COMPLETED · Phase 3
-
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
RECRUITING · Phase 1
-
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
RECRUITING
-
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies
ACTIVE NOT RECRUITING
-
A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
COMPLETED · Phase 1
-
A Study of EDP-323 in Healthy Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
- NCT03474913 · 550 participants
Upright MRI for Prostate Cancer Screening
- NCT04761120 · 550 participants
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI